Amjevita
Amjevita is a biosimilar medication to adalimumab, which is used to treat various autoimmune diseases. It is produced by Amgen, a leading biotechnology company. Amjevita is designed to mimic the effects of adalimumab, providing similar therapeutic benefits for conditions such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, and plaque psoriasis.
Development and Approval[edit | edit source]
Amjevita was developed by Amgen as a biosimilar to Humira, a widely used adalimumab product. The United States Food and Drug Administration (FDA) approved Amjevita in September 2016, making it one of the first biosimilars to adalimumab available in the United States. The approval was based on comprehensive data demonstrating that Amjevita is highly similar to Humira in terms of safety, purity, and potency.
Mechanism of Action[edit | edit source]
Amjevita works by targeting and inhibiting tumor necrosis factor alpha (TNFα), a pro-inflammatory cytokine involved in the inflammatory response. By blocking TNFα, Amjevita helps reduce inflammation and other symptoms associated with autoimmune diseases.
Indications[edit | edit source]
Amjevita is indicated for the treatment of:
- Rheumatoid arthritis in adults
- Juvenile idiopathic arthritis in patients aged 2 years and older
- Psoriatic arthritis in adults
- Ankylosing spondylitis in adults
- Crohn's disease in adults and children aged 6 years and older
- Ulcerative colitis in adults
- Plaque psoriasis in adults
Administration[edit | edit source]
Amjevita is administered via subcutaneous injection. The dosage and frequency of administration depend on the specific condition being treated and the patient's response to therapy.
Side Effects[edit | edit source]
Common side effects of Amjevita include:
- Injection site reactions
- Upper respiratory infections
- Headache
- Rash
- Nausea
Serious side effects may include:
- Serious infections
- Malignancies
- Hepatitis B reactivation
- Heart failure
- Nervous system problems
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
